Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-29T06:11:12.870Z Has data issue: false hasContentIssue false
  • English
  • Français

Currents in Contemporary Ethics: The Implications of Expanding Access to Unapproved Drugs

Published online by Cambridge University Press:  01 January 2021

Meghan K. Talbott
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
JLME Column
Information
Journal of Law, Medicine & Ethics , Volume 35 , Issue 2 , Summer 2007 , pp. 316 - 319
Copyright
Copyright © American Society of Law, Medicine and Ethics 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Mark A. Rothstein serves as the section editor for “Currents in Contemporary Ethics.” Professor Rothstein is the Herbert F. Boehl Chair of Law and Medicine and the Director of the Institute for Bioethics, Health Policy and Law at the University of Louisville School of Medicine in Kentucky. (mark.rothstein@louisville.edu)

References

21 C.F.R. § 312.34 (2006).CrossRefGoogle Scholar
Id. § 312.34(c).Google Scholar
FDA News Release, “FDA Proposes Rules Overhaul to Expand Availability of Experimental Drugs,” available at <http://www.fda.gov/bbs/topics/NEWS/2006/NEW01520.html?> (last visited March 6, 2007).+(last+visited+March+6,+2007).>Google Scholar
Expanded Access to Investigational Drugs for Treatment Use, 71 Fed. Reg. 75147–75168 (December 14, 2006) (to be codified at 21 C.F.R. pt. 312).Google Scholar
Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 445 E. 3d 470, 473 (D.C. Circuit 2006) (vacated for rehearing en banc) [hereinafter cited as Abigail Alliance]; Okie, S., “Access before Approval – A Right to Take Experimental Drugs,” New England Journal of Medicine 355, no. 5 (2006): 437–440; Marti Nelson Cancer Foundation/CancerActionNow.org, “Expanded Access: Our Efforts,” available at <http://www.canceractionnow.org/advocacy/expandedaccess.php> (last visited March 5, 2007).Google Scholar
Abigail Alliance, 445 F.3d 470.Google Scholar
Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, No. 04–5350, 2006 U.S. App. LEXIS 28974 (D.C. Circuit November 21, 2006).Google Scholar
See Expanded Access to Investigational Drugs for Treatment Use, 71 Fed. Reg. at 75,150.Google Scholar
Id.Google Scholar
Id., at 75,148.Google Scholar
Id.Google Scholar
21 C.F.R. § 312.34(a).Google Scholar
Class, T., “Expanded Access to Unapproved Medical Products: Compassionate Use,” Regulatory Affairs Focus magazine, May 2006, available at <http://www.raps.org/s_raps/rafocus_article.asp?TRACKID=&CID=61&DID=2720> (last visited March 8, 2007).+(last+visited+March+8,+2007).>Google Scholar
21 C.F.R. § 312.34(b)(1)(iv).Google Scholar
Id. § 312.34(b)(2)-(3).Google Scholar
Id. § 312.34(a).Google Scholar
Id.Google Scholar
Id. § 312.34(b)(3).Google Scholar
Id. § 312.34(b)(2).Google Scholar
See Okie, supra note 5.Google Scholar
Id.Google Scholar
Abigail Alliance, 445 F.3d at 473.Google Scholar
Id.Google Scholar
Id., at 473–474.Google Scholar
Id., at 475.Google Scholar
Id., at 475–487.Google Scholar
Id., at 484, 486.Google Scholar
Id., at 480–483.Google Scholar
Id., at 484–485.Google Scholar
Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, No. 04–5350, 2006 U.S. App. LEXIS 28974 (D.C. Circuit November 21, 2006).Google Scholar
Expanded Access to Investigational Drugs for Treatment Use, 71 Fed. Reg. 75,147, 75,150 (December 14, 2006) (to be codified at 21 C.F.R. pt. 312).Google Scholar
Id.Google Scholar
Id., at 75,166.Google Scholar
Id., at 75,151.Google Scholar
Id., at 75,151.Google Scholar
Abigail Alliance, 445 F.3d at 473.Google Scholar
Expanded Access to Investigational Drugs for Treatment Use, 71 Fed. Reg. at 75,166–75,167.Google Scholar
Id., at 75,167.Google Scholar
Id., at 75,166.Google Scholar
Id.Google Scholar
Milligan, R. and Bailey, B., “Physician Participation in Clinical Trials: The Rewards Are Obvious, but Risks Are Real,” April 1, 2005, available at <http://www.hg.org/articles/article_1080.html> (last visited March 6, 2007).+(last+visited+March+6,+2007).>Google Scholar
21 C.F.R §§ 56.109, 56.111.Google Scholar
Abney v. Amgen, Inc., 443 F.3d 540 (6th Circuit 2006); see Milligan, supra note 40.Google Scholar
Expanded Access to Investigational Drugs for Treatment Use, 71 Fed. Reg. at 75,150.Google Scholar
Id.Google Scholar
See Milligan, and Bailey, supra note 41.Google Scholar
E. Nichols and the Institute of Medicine, Expanding Access to Investigational Therapies for HIV Infection and AIDS, March 12–13, 1990 Conference Summary (Washington, D.C.: National Academy Press, 1991): at 50.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Expanded Access to Investigational Drugs for Treatment Use, 71 Fed. Reg. 75,147, 75,158 (Dec. 14, 2006) (to be codified at 21 C.F.R. pt. 312).Google Scholar
Mello, M., Studdert, D. and Brennan, T., “The Rise of Litigation in Human Subjects Research,” Annals of Internal Medicine 139 (2003): 40–45, at 41.CrossRefGoogle Scholar
See Class, supra note 13.Google Scholar
See Expanded Access to Investigational Drugs for Treatment Use, 71 Fed. Reg. at 75,166.Google Scholar
Charging for Investigational Drugs, 71 Fed. Reg. 75,168, 75,170 (Dec. 14, 2006) (to be codified at 21 C.F.R. pt. 312).Google Scholar
Id., at 75,170.Google Scholar